Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Edith A. Perez

Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida

Abstract

Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis. In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clinical efficacy. Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs. This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents.

Introduction

Microtubules are components of the cytoskeleton with important roles in a variety of cellular functions such as intracellular transport, maintenance of cell shape, polarity, cell signaling, and mitosis (1). During mitosis, microtubules form the mitotic spindle that transports daughter chromosomes to separate poles of the dividing cell. The important role of microtubules in cell division makes them a desirable target for the development of chemotherapeutic agents directed against rapidly dividing cancer cells. Microtubule inhibitors (MTI) include agents such as taxanes, vinca alkaloids, and epothilones that are used against many solid and hematologic malignancies. Although MTIs have significant clinical activity in multiple tumor types, their effectiveness is reduced by drug resistance mechanisms. As a result, there is an ongoing effort to develop new agents within this class to improve efficacy and circumvent drug resistance. The development of new MTIs would benefit from a better understanding of microtubule structure, dynamics, and the different mechanisms of action of currently available agents.

Microtubule Structure

Microtubules are noncovalent polymers of α- and β-tubulin heterodimers assembled in a filamentous tube-shaped structure. The two 50-kDa subunits (α- and β-tubulin) are ~50% identical to one another (2) and polymerize by nucleation-elongation, in which noncovalent tubulin dimers are added at the ends of a short microtubule “nucleus” (3). In the polymerization stage, the tubulin heterodimers lay head to tail, with the α-subunit of one dimer in contact with the β-subunit of the next. The resulting protofilaments comprise the backbone of the hollow, cylindrical microtubule that is approximately 25 nm in diameter. The microtubule consists of the parallel arrangement of 13 protofilaments in an imperfect helix (3). The head-to-tail order of the α/β-tubulin dimers confers polarity on the microtubule with one end ringed with α-tubulin, and the other end ringed with β-tubulin. These are considered the (−) and (+) ends, respectively (3). The microtubule-organizing center (MTOC) is a network of microtubule-associated proteins (MAP) to which the microtubules are attached. The (−) ends of microtubules are anchored to the MTOC, whereas the (+) ends are distal (1). Microtubules exist in a dynamic state, growing and shortening by the reversible association and dissociation of α/β-tubulin heterodimers at both ends. The α-tubulin ringed (−) end is less dynamic, whereas the more dynamic β-tubulin ringed (+) end grows and shortens more rapidly (2).

Each subunit has a guanosine triphosphate (GTP) binding site; termed the nonexchangeable site in α-tubulin, and the exchangeable site in β-tubulin. Though the GTP bound to α-tubulin is stable, the GTP in β-tubulin is hydrolyzed to guanosine diphosphate (GDP) after polymerization (1). The rate of tubulin addition is faster than the rate of GTP hydrolysis during polymerization, allowing for the formation of a protofilament. The stability of the microtubule depends on whether the exchangeable site of the β-tubulin is occupied by GDP or GTP. A GTP-capped microtubule is stable and will continue to grow, whereas a microtubule capped with GDP-bound β-tubulin at the (+) end is unstable and will depolymerize rapidly (1, 3). Hence, microtubule growth involves the association of GTP-bound subunits,
and shortening involves the dissociation of GDP-bound subunits. Microtubule shortening occurs when the rate of tubulin addition is so slow that the hydrolysis event occurs before additional subunits can be incorporated (3). Consequently, the rate of GTP-bound tubulin addition is another factor that determines microtubule stability. A shrinking microtubule may be “rescued” if GTP-bound subunits are added to the exposed (+) end before the bound GTP is hydrolyzed (3).

**Microtubule Dynamics**

The GTP binding and hydrolysis events allow microtubules to exhibit two dynamic behaviors: dynamic instability and treadmilling (3). Dynamic instability is characterized by the stochastic switching of microtubules between periods of slow growth, rapid shortening, and attenuation (a pause in which neither growth nor shortening is detectable; ref. 3). Transition from a growth stage to shortening is referred to as a “catastrophe”; transition from a shortening stage to growth is called a “rescue.” (3) Treadmilling is the net addition of a tubulin subunit to the (+) end, and the corresponding loss at the (−) end (3). Microtubule dynamics are important for successful mitosis, particularly for the proper function of the mitotic spindle (3). To ensure the rapid assembly and disassembly of microtubules during the alignment and separation of chromosomes, spindle microtubules are more dynamic than interphase microtubules (3). Disruption of microtubule dynamics by compounds that inhibit mitosis prevents cell cycle progression with arrest in the G2/M phase, eventually resulting in apoptotic cell death (3).

MTIs are classified into two groups: stabilizing and destabilizing agents (Table 1). Microtubule-stabilizing agents, including taxanes and epothilones, operate by promoting polymerization and increasing the microtubule polymer mass in cells. Destabilizing agents, such as the vinca alkaloids, depolymerize microtubules, inhibit polymerization, and decrease polymer mass. At low concentrations, however, both stabilizers and destabilizers suppress microtubule dynamics without changing polymer mass (2, 3). As the understanding of the action of MTIs at the molecular level increases, differences in mechanisms of action of these agents are being elucidated. These differences may be the basis of observed disparities in activity and tolerability of MTIs.

**Microtubule-Destabilizing Agents**

**Vinca**

Vinca alkaloids were originally isolated from the *Vinca rosea* plant, which is also known as *Catharanthus roseus*. Vinca alkaloids are dimeric molecules, consisting of catharanthine (velbanamine) and vindoline moieties (Fig. 1). The first two vinca alkaloids identified, vinblastine and vincristine, are almost structurally identical, except for the formyl group attached to the dihydroindole nitrogen in vincristine, whereas vinblastine has a methyl group at that position (Fig. 1). Vinorelbine (navelbine, GlaxoSmithKline) is a semisynthetic derivative of vinblastine, which has an eight-membered ring in the catharanthine moiety instead of the nine-membered ring in the parent vinblastine (Fig. 1).

The vinca-binding domain on β-tubulin is located near the exchangeable GTP binding site (Table 2). Vinca alkaloids have two distinct binding sites on microtubules: binding with high affinity to tubulin at the microtubule ends, but with low affinity to tubulin along the sides of the microtubule surface (4, 5). They also increase the affinity of tubulin for itself, leading to the formation of spiral aggregates (4). Vinca alkaloids are classified as destabilizing agents that cause microtubule depolymerization, suppress treadmilling and dynamic instability, inhibit mitotic progression, and ultimately result in cell death by apoptosis.

The vinca alkaloids are part of treatment regimens commonly used to treat patients with solid tumors or hematologic malignancies, and have shown activity as single agents or in combination with other cytotoxic agents.

**Microtubule-Stabilizing Agents**

**Taxanes**

Paclitaxel (taxol, Bristol-Myers Squibb) is a natural product isolated from *Taxus brevifolia* (6). Docetaxel (taxotere, Sanofi-Aventis) is a water-soluble, semisynthetic analog of the naturally occurring precursor 10-deacetylbaccatin III, which was isolated from *Taxus baccata*. Taxanes are complex diterpenes with a tetracyclic core consisting of two cyclohexanes (rings A and C), a cyclooctane (ring B), and an octane (ring D). Paclitaxel and docetaxel have an ester side chain at the 13′ position; however, docetaxel is deacetylated at the 10′ position, and has a trimethyl group attached to the amide tail, whereas paclitaxel has a phenyl group at that position (Fig. 1).

Both paclitaxel and docetaxel occupy the same binding site in the β-subunit of tubulin with a 1:1 stoichiometry (Table 2; refs. 3, 5, 7, 8). The taxane binding site is on the interior surface of microtubules, resulting in the stabilization of microtubules, increased polymerization, and the suppression of microtubule dynamics, leading to cell cycle arrest in the G2/M phase and ultimately, apoptosis (Table 3; refs. 3, 5, 8). At high concentrations, taxanes increase polymer mass by inhibiting the dissociation of tubulin yet allowing addition at both ends of the microtubule (3, 5, 8).

Demonstrating significant activity against solid tumors when used either as single agents or in combination with other chemotherapeutic or targeted agents, paclitaxel and docetaxel have been approved for the treatment of breast and non-small cell lung cancer (NSCLC; refs. 9, 10). Paclitaxel is also indicated as therapy for the treatment of advanced carcinoma of the ovary, whereas docetaxel is also indicated for treatment of androgen-independent (hormone refractory) metastatic prostate cancer, advanced gastric adenocarcinoma, and locally advanced squamous cell carcinoma of the head and neck (SCCHN; refs. 9, 10). Albumin-bound paclitaxel (Abraxane, Abraxis Oncology), a cremophor-free formulation of paclitaxel, has also shown activity in phase II-III trials in metastatic breast cancer (MBC) and is indicated for the treatment of breast...
cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy (11).

**Resistance**

Intrinsic or acquired resistance is a widespread occurrence that limits the efficacy of many chemotherapeutic drugs, including MTIs. One common mechanism of resistance identified in preclinical studies involving the P-glycoprotein (P-gp) efflux pump, which is a product of the multidrug resistance gene (MDR1; ref. 12). This membrane-associated ATP-binding cassette transporter (ABC-transporter) is overexpressed in many tumor cell lines, and decreases intracellular drug levels, consequently limiting drug cytotoxicity (12). The reversal of drug resistance by P-gp inhibitors has been shown in vitro (12). However, the role of MDR1/P-gp in clinical resistance to therapeutic agents has not been validated because of the paucity of studies in which patient tumor specimens have been tested for P-gp expression. In phase 3 clinical trials, agents such as cyclosporine A, verapamil, and valsparod did not improve clinical outcome. In patients with chemoresistant disease, the addition of the P-gp inhibitor tariquidar (XR9576) had minimal ability to restore sensitivity to chemotherapy (13). A new P-gp inhibitor zosuquidar (LY335979) was evaluated in phase 1 trials and only modestly increased the plasma concentrations of doxorubicin and docetaxel (14). The effects of this P-gp inhibitor on clinical resistance to docetaxel is being investigated in advanced breast cancer (14).

Alterations in tubulin-binding sites or microtubule dynamics may play a role in the mechanism of resistance to taxanes and vinca alkaloids. Analyses of paclitaxel-resistant ovarian cancer cells showed mutations in the β1 isotype of tubulin encoded by the M40 gene (F270V and A364T; ref. 15). Altered expression of tubulin isotypes also have an impact on microtubule dynamics. Microtubules consisting of the βIII-tubulin isotype have altered assembly properties, requiring a larger critical mass of tubulin for assembly, and polymerizing at a slower rate than other isotypes (16). In vitro, the overexpression of βIII tubulin results in increased resistance to taxane and vinorelbine (17, 18). Elevated expression of βIII tubulin has also been correlated with clinical resistance to taxanes in a number of human cancers (19). For example, in a study examining predictors of response to paclitaxel, disease progression was observed in a minority (2%) of breast cancer patients whose tumors had low expression of βIII tubulin. By contrast, 38% of patients with elevated expression of βIII tubulin progressed during treatment with paclitaxel (20). Similar results were observed in a second study evaluating paclitaxel as first-line containing chemotherapy in patients with advanced breast cancer (21). An association between elevated expression of βIII and β1 tubulin isotypes in breast tumors and poor response to docetaxel-based chemotherapy has also been reported (22). Patients whose tumors had elevated expression of both βIII and β1 tubulin had the poorest response rate (15%), compared with patients with elevated expression of only one of the isotypes (50%), or patients with low expression of both isotypes (75%; ref. 22). High expression of βIII-tubulin has also been associated with poor response to taxane-based chemotherapy in NSCLC and ovarian cancer (23, 24).

Other proteins such as stathmin, MAP4, γ-actin, and tau may influence resistance to MTIs. In breast cancer cells, the overexpression of stathmin, a regulatory protein that destabilizes microtubules, decreased sensitivity to paclitaxel and vinblastine (25). Higher levels of MAP4 in multiple cancer cell lines increased sensitivity to paclitaxel, but decreased sensitivity to vinca alkaloids (26, 27). MAP4 promotes the polymerization of microtubules, which could explain the disparate response to taxanes (stabilizing agents) and vinca alkaloids (destabilizing agents). Another potential mechanism of resistance involves the cytoskeletal protein γ-actin. A basic isoform (γ-actin 2) is expressed in vinblastine-resistant leukemia cells, and single-point mutations in the γ-actin of NIH 3T3 cells resulted in resistance to MTIs (28). Analysis of the status of γ-actin in relapsed patients with acute lymphoblastic leukemia seemed to suggest a correlation between the reduced expression of γ-actin and the risk of relapse (28). A growing body of evidence indicates that elevated expression of the MAP tau is associated with resistance to paclitaxel (19). However, an analysis of predictive and or prognostic factors in a large phase III study (NSABP-B, ref. 29) in patients with nodal-positive breast cancer did not show an association between

<table>
<thead>
<tr>
<th>Table 1. Classes of MTIs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Compound class</strong></td>
</tr>
<tr>
<td>Taxanes</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Epothilones</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Vinca alkaloids</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Halichondrin b</td>
</tr>
</tbody>
</table>

Mol Cancer Ther 2009;8(8). August 2009

Downloaded from mct.aacrjournals.org on July 15, 2021. © 2009 American Association for Cancer Research.
tau expression levels and benefit from paclitaxel-based chemotherapy (29).

Thus, current evidence indicates that altered drug-binding sites, microtubule-interacting proteins, and impaired assembly properties may be intrinsic or acquired mechanisms that confer resistance to MTIs; however, the clinical relevance of these resistance mechanisms is not completely understood.

**Novel Microtubule Inhibitors in Development**

With the aforementioned issues in mind, novel MTIs are being investigated to offer more effective therapeutic

![Chemical structures of MTIs](image)

**Figure 1.** Chemical structures of MTIs.
options. One rationale for the continued development of novel agents is the potential of improving drug activity by exploiting the differences in mechanism of action.

**Epothilones**

The epothilones are 16-membered macrolides named for their molecular structure, which includes an epoxide, methyl thiazole, and ketone (Fig. 1; ref. 30). Epothilones A and B were originally isolated from the myxobacterium *Sorangium cellulosum* (30). The structures of the two compounds are nearly identical, with the exception of substitution of a hydrogen for a methyl group at position C-12 in the epothilone B molecule (Fig. 1).

Epothilones are microtubule stabilizing agents with a mechanism of action similar to that of taxanes, including suppression of microtubule dynamics, stabilization of microtubules, promotion of tubulin polymerization, and increased polymer mass at high concentrations (Table 2; refs. 31–33). They induce mitotic arrest in the G2-M phase of the cell cycle, resulting in apoptosis (Table 3; refs. 31–33). Similar to paclitaxel, cells exposed to epothilones A and B are characterized by extensive microtubule bundles within the cytoplasm and the formation of aberrant mitotic spindles (31, 32). Both compounds compete with paclitaxel for binding to tubulin and are able to displace [3H]-paclitaxel from microtubules, suggesting that they occupy the same binding site as taxanes (31, 32). Despite these similarities, analysis using electron crystallography has shown that epothilones interact with the β-subunit of tubulin through unique and independent molecular interactions (34). The benzoyl phenyl residues of epothilone A were shown to reside in a region of the β-tubulin pocket that is not occupied by paclitaxel. Moreover, four out of the five oxygen-containing polar groups within epothilone A have unique contacts with the β-tubulin protein that are not shared by paclitaxel (34). Three unique molecular interactions were identified that are critical to epothilone A binding with β-tubulin pocket. Threonine 274 and arginine 282 of β-tubulin form cooperative hydrogen bonds with the C3, C5, and C7 oxygens of epothilone A that are necessary for binding (34). In addition, glutamine 292 of β-tubulin forms a hydrogen bond with leucine 275 that is essential to stabilization of the M loop conformation and cooperative hydrogen bonding to epothilone A (34). Alanine 231 also forms a hydrogen bond with histidine 22 that anchors epothilone A within the β-tubulin pocket (34). By contrast, the C3 and C4 substituent groups of paclitaxel form essential contacts with phenylalanine 270 of the β-tubulin protein, a residue that does not play a critical role in epothilone A binding (34).

In *in vitro* studies in tumor cell lines show that epothilone B is more active than epothilone A. Both epothilones have greater potency than paclitaxel or docetaxel in *in vitro*, with mean inhibitory concentration (IC50) values in the low nanomolar range (31, 32). The distinct mechanism of binding of epothilones to β-tubulin may contribute, at least in part, to their increased potency and to a broader spectrum of activity compared with taxanes, including their ability to stabilize yeast microtubules (35). The epothilones are also active against cells that overexpress P-gp (32, 36), a mechanism implicated in development of resistance to taxanes (12, 37). In addition, mutations in β-tubulin that confer resistance to taxanes (15) did not significantly alter the cytotoxicity of epothilones A and B. Single point mutations (T274I and R282Q) in β1-tubulin, the major β-tubulin isotype expressed in A2780 ovarian carcinoma cells, are associated with resistance to epothilones A and B in vitro (15). However, the prevalence of these β-tubulin mutations and their clinical implications have not been clearly elucidated. The promising anticancer activity of epothilones A and B and their ability to overcome resistance have raised interest in this class of compounds and resulted in the synthesis and evaluation of several epothilone analogs. Ixabepilone is the first of this class of antineoplastic agents to be approved for the treatment of cancer, and other compounds in this class are undergoing clinical evaluation for the treatment of a variety of tumor types (38). A summary of chemical-biological properties and activity of lead compounds in this class is provided below.

**Epothilone B Analog Ixabepilone**

A semisynthetic derivative of epothilone B, ixabepilone (aza-epothilone B or BMS247550, Bristol-Myers Squibb) was synthesized by converting the lactone of patupilone to a lactam (36). This structural modification resulted in improved solubility, low plasma protein binding, and high metabolic stability (39, 40). Like the natural epothilones A and B, ixabepilone stabilizes microtubules and induces apoptosis (31, 39–42). In preclinical studies, ixabepilone showed activity against human and murine xenografts *in vivo*, and maintained activity in paclitaxel-resistant cell lines and tumors, including those with elevated expression of P-gp and or β-tubulin III isotype (31, 36, 38–43).

An important feature of ixabepilone is its unique mechanism of action (44, 45). Paclitaxel-induced apoptosis in HL-60 leukemia cells has been linked to a mitochondrial-mediated pathway involving cytochrome C release and activation of Apaf-1 and caspase-9 (46–48). By contrast, in Jurkat human acute leukemia cells, ixabepilone-induced apoptosis is linked to a mitochondrial-mediated pathway involving cytochrome C release and activation of Apaf-1 and caspase-9 (46–48). By contrast, in Jurkat human acute leukemia cells, ixabepilone-induced apoptosis is linked to a mitochondrial-mediated pathway involving cytochrome C release and activation of Apaf-1 and caspase-9 (46–48). By contrast, in Jurkat human acute leukemia cells, ixabepilone-induced apoptosis is linked to a mitochondrial-mediated pathway involving cytochrome C release and activation of Apaf-1 and caspase-9 (46–48). By contrast, in Jurkat human acute leukemia cells, ixabepilone-induced apoptosis is linked to a mitochondrial-mediated pathway involving cytochrome C release and activation of Apaf-1 and caspase-9 (46–48). By contrast, in Jurkat human acute leukemia cells, ixabepilone-induced apoptosis is linked to a mitochondrial-mediated pathway involving cytochrome C release and activation of Apaf-1 and caspase-9 (46–48).
expression of PUMA) and transcription-independent (direct translocation of p53 to the mitochondria) mechanisms (Table 3; ref. 52). These mechanistic differences may underlie the antitumor activity of ixabepilone observed in taxane-resistant and or refractory tumors.

Ixabepilone has shown efficacy in chemo-naive or pretreated patients with breast cancer, and is typically administered once every 3 weeks as a 3-hour IV infusion of a 40 mg/m² dose (44, 53). Clinical activity of ixabepilone has also been reported in other tumor types including prostate, renal, NSCLC, and pancreatic cancers (38). A phase 2 trial in patients with MBC resistant to an anthracycline, a taxane, and capecitabine showed a response rate of 12% with stabilization of disease in an additional 50% of patients (54). Ixabepilone treatment led to durable responses in this highly chemoresistant patient population, even in patients who had not responded to multiple previous therapies (54). Consistent with these results, a 12% response rate was reported in a phase 2 trial in patients with taxane-resistant MBC (55). All patients received prior anthracycline-based therapy and 73% of patients experienced disease progression within 1 month of their last taxane dose. Five of the six patients that responded to ixabepilone did not respond to prior taxane therapy (55). A 42% response rate was reported in a phase 2 trial in MBC patients treated with ixabepilone as first-line chemotherapy for metastatic disease (56). In addition, ixabepilone, monotherapy was active in the neoadjuvant setting in patients with invasive breast cancer not amenable to breast conservation surgery (BCS; ref. 57). Patients received ixabepilone monotherapy for a maximum of four cycles. A 61% best overall response rate was reported, with pathologic complete responses in the breast (pCRb) in 18% of patients. Thirty-two percent of patients who had surgery underwent BCS (57). A recent phase 3 trial evaluated the efficacy of ixabepilone in combination with capecitabine in patients with MBC who experienced disease progression after treatment with anthracyclines and taxanes (58). The ixabepilone plus capecitabine regimen was superior to capecitabine monotherapy, resulting in a significant clinical benefit in patients resistant to anthracyclines and taxanes (58).

The main treatment-related adverse events associated with ixabepilone therapy are similar to those reported with other MTIs such as taxanes (44, 53). The treatment-limiting toxicity is grade 3-4 neuropathy. Ixabepilone-induced neuropathy is primarily sensory and reversible after dose reductions. The most common hematologic adverse events include grade 3-4 neutropenia and leucopenia. Other adverse events include fatigue, arthralgia, myalgia, and diarrhea (44, 53, 59).

Based on results of the phase II-III trials, ixabepilone was the first epothilone to be approved by the U.S. Food and Drug Administration (FDA) and is indicated in combination with capecitabine for treatment of MBC or locally advanced breast cancer resistant or refractory to treatment with an anthracycline and a taxane, or as monotherapy for treatment of MBC or locally advanced breast cancer resistant-refractory to anthracyclines, taxanes, and capecitabine.

**Epothilone B (Patupilone, EPO906)**

Epothilone B (Novartis) has been evaluated in clinical trials against a variety of solid tumors. Patupilone crosses the blood-brain barrier and has shown activity in patients with recurrent or progressive brain metastases from NSCLC (60). Patupilone is typically administered as a 5- to 20-minute IV infusion of 2 to 10 mg/m². The most commonly reported grade 3-4 adverse events are diarrhea (the dose-limiting toxicity), nausea, and fatigue (60). In an ongoing phase 3 trial, patupilone is being compared with pegylated liposomal doxorubicin in pretreated patients with ovarian cancer (61).

**Epothilone D and Analogs (KOS-862 and KOS-1584)**

KOS-862, also known as epothilone D and desoxyepothilone B, (Kosan Biosciences) lacks the epoxide moiety in epothilone B (Fig. 1; ref. 36). The compound has a mechanism of action similar to that of taxanes, leading to microtubule stabilization and mitotic arrest. KOS-862 has shown superior in vivo anticancer activity relative to patupilone (36). In phase 2 trials, KOS-862 showed activity in chemo-naive or pretreated patients with breast cancer and NSCLC (62). The most common adverse events noted were grade 1-2 neuropathy, fatigue, nausea, and vomiting (62). Clinical development of KOS-862 has been discontinued.

KOS-1584 (9,10-didehydroepothilone D; Kosan Biosciences) is a novel analog of KOS-862 (Fig. 1). The compound was identified in screens for epothilone analogs with higher potency and improved pharmacologic-pharmacokinetic (PK) properties (63, 64). KOS-1584 stabilizes microtubules, leading to G2-M arrest and apoptosis. KOS-1584 has shown approximately 3- to 12-fold higher potency compared with KOS-862, enhanced tumor tissue penetration, and reduced exposure to selected tissues including CNS (63, 64). An ongoing phase 2 trial is evaluating efficacy of KOS-1584 in patients with advanced or metastatic (stage IIIIB-IV) NSCLC (65).

**Vinca Alkaloids, Vinflunine**

Vinflunine is a novel MTI of the vinca alkaloid class that was synthesized from a vinca precursor compound by the introduction of two fluorine atoms at the 20’ position, and simultaneous reduction of an adjacent 3’, 4’ double bond in the catharanthine moiety (Fig. 1; refs. 66, 67). Vinflunine destabilizes microtubules, decreases the microtubule growth rate and the time spent in attenuation. Vinflunine presents a differential affinity for tubulin with a higher reversibility of interaction with its target (58, 59). This unique mechanism of action may underlie the superior in vivo activity observed with vinflunine compared with other vinca alkaloids (66, 67). In phase 1 pharmacokinetic studies, the active metabolite of vinflunine 4-O-deacetylvinflunine was found to have a half-life of ~5 days (68). Furthermore, as a weak substrate for P-gp, in vitro and in vivo resistance to vinflunine develops at a slow rate (66, 67).

Vinflunine is freely water soluble, thus eliminating the need for solvent-based formulation and consequently steroid premedication. Administered as a 10- to 20-minute
intravenous (IV) infusion of 320 mg/m² once every 3 weeks, vinflunine has anticancer activity against many tumor types (68). Recently completed clinical trials showed the activity of vinflunine in patients with advanced transitional cell carcinoma of the urothelium (TCCU; refs. 69, 70), breast (71), NSCLC (72), and malignant pleural mesothelioma (73). In a recently reported phase 3 trial, the efficacy of vinflunine was equivalent to docetaxel in pretreated patients with NSCLC (74).

Vinflunine-related adverse events were not cumulative and included mostly grade 3-4 neutropenia, fatigue, and constipation (69, 71).

**Halichondrin B Analog Erubilin Mesylate**

Erubilin mesylate (E7389, Eisai Medical Research) is a truncated analog of the polyether macrolide natural product halichondrin B, which was isolated from the marine sponge *Halichondria okadai* in 1986 (74). Halichondrins are noncompetitive inhibitors of vinca alkaloids that occupy the vinca-binding domain on tubulin, suppress the growth of microtubules, and inhibit polymerization, thereby inducing cell cycle arrest and apoptosis (75). The halichondrin analog erubilin mesylate (also known as E7389, ER-086526, and NSC 707389) inhibits the polymerization of purified tubulin more potently than the parent compound halichondrin B (76). Erubilin mesylate has a unique interaction with tubulin as it inhibits microtubule growth with no effect on shortening events (74). Referred to as having an “end-poisoning” mechanism of action, erubilin mesylate either binds directly to the microtubule ends or induces tubulin aggregates, which compete with soluble tubulin for addition to the growing ends of the microtubule (74).

**Table 2. Tubulin/microtubule-binding properties of MTIs**

<table>
<thead>
<tr>
<th>Property</th>
<th>MTI class</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vinca alkaloids</strong></td>
<td><strong>Taxanes-paclitaxel</strong></td>
</tr>
<tr>
<td>Mechanism of action</td>
<td>Direct binding to β-subunit of α/β-tubulin dimers</td>
</tr>
<tr>
<td>Binding site</td>
<td>Binds to β-tubulin at site near exchangeable GTP-binding site</td>
</tr>
<tr>
<td>Biochemical effect(s)</td>
<td>Suppress microtubule dynamics</td>
</tr>
<tr>
<td></td>
<td>Suppress microtubule assembly</td>
</tr>
<tr>
<td></td>
<td>Induce microtubule depolymerization</td>
</tr>
<tr>
<td></td>
<td>Suppress microtubule treadmilling</td>
</tr>
<tr>
<td></td>
<td>Suppress microtubule dynamic instability</td>
</tr>
<tr>
<td></td>
<td>Induce tubulin association into coiled spiral aggregates</td>
</tr>
<tr>
<td></td>
<td>Decrease polymer mass at high concentrations</td>
</tr>
<tr>
<td>Selectivity</td>
<td>No difference in β-tubulin isotype binding affinity</td>
</tr>
<tr>
<td></td>
<td>Higher affinity for α/βII and α/βIII tubulin dimers in the presence of GTP observed for vincristine</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NOTE: See refs. 3, 5, 7, 8, 31, 34, 35, 42, 85, 86.*
In phase 2 trials, erubilin mesylate has been evaluated in previously treated or treatment-resistant patients with NSCLC, breast, and prostrate cancer (77–79). The recommended dosing schedule of erubilin mesylate is 1.4 mg/m² administered as a 2- to 5-minute IV bolus on days 1 and 8 of a 21-day cycle. The toxicities associated with erubilin mesylate include grade 3-4 neutropenia, anemia, and peripheral neuropathy (77–79). On days 1 and 8 of a 21-day cycle, the main grade 3-4 adverse events reported were neutropenia, anemia, and diarrhea (83, 84). Further investigations are warranted, because no trials have directly compared the efficacy of DJ-927 with that of docetaxel or paclitaxel.

**Taxane Analog DJ-927**

DJ-927 (Daichi Sankyo Inc.) is a novel docetaxel analog with improved solubility and oral bioavailability (82). With a similar mechanism of action to paclitaxel and docetaxel, DJ-927 is a microtubule-stabilizing agent that has greater potency than paclitaxel or docetaxel against a variety of tumor cell lines in vitro and in vivo (82). DJ-927 retains activity against P-gp-expressing cells, which could potentially translate to reduced clinical resistance. Intracellular amounts of DJ-927 were higher than paclitaxel and docetaxel in P-gp-positive and -negative cells, and the addition of the P-gp inhibitor verapamil did not affect the in vitro activity of DJ-927 (82).

The orally bioavailable DJ-927 has shown promising activity in clinical trials either as a single agent or in combination with other cytotoxic agents. DJ-927 seems active after prior chemotherapy and has a manageable toxicity profile in pretreated patients with gastric and colorectal cancers (Table 2; refs. 83, 84). Administered orally at a dose of 27 mg/m² or 35 mg/m² once every 3 weeks, the main grade 3-4 adverse events reported were neutropenia, anemia, and diarrhea (83, 84). Further investigations are warranted, because no trials have directly compared the efficacy of DJ-927 with that of docetaxel or paclitaxel.

**Conclusions**

MTIs are an important class of compounds in the chemotherapeutic armamentarium. Disparities in their microtubule-binding properties lead to differences in their mechanisms of action with a significant impact on the efficacy or toxicity profile of each agent. Newer agents have shown promising results in clinical settings and may offer improvements in efficacy, tolerability, and the ability to at least partially overcome resistance. Evaluation of combinations of these agents with other targeted and biological therapies for malignancies is an important strategy to follow.

**Disclosure of Potential Conflicts of Interest**

Dr. Edith A. Perez received research funding from GlaxoSmith, Bristol-Myers Squibb, and Sanofi-Aventis.
Differentially Microtubule Inhibitors

References
11. Abramis Oncology; Bridgewater (NJ). Prescribing information for Abraxane Oncology; SABCS Meeting; 2008.


76. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 703789 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70:1866–75.


Correction: Microtubule Inhibitors: Differentiating Tubulin-Inhibiting Agents Based on Mechanisms of Action, Clinical Activity, and Resistance

In this article (Mol Cancer Ther 2009;8:2086–95), which was published in the August 2009 issue of *Molecular Cancer Therapeutics* (1), the compound eribulin mesylate was misspelled as erublin mesylate.

The online version has been corrected and no longer matches the print version. The author regrets this error.

Reference

Molecular Cancer Therapeutics

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Edith A. Perez


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-09-0366</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cited articles</td>
<td>This article cites 74 articles, 28 of which you can access for free at: <a href="http://mct.aacrjournals.org/content/8/8/2086.full#ref-list-1">http://mct.aacrjournals.org/content/8/8/2086.full#ref-list-1</a></td>
</tr>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 30 HighWire-hosted articles. Access the articles at: <a href="http://mct.aacrjournals.org/content/8/8/2086.full#related-urls">http://mct.aacrjournals.org/content/8/8/2086.full#related-urls</a></td>
</tr>
</tbody>
</table>

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/8/8/2086. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |